kineta - Kineta Completes Reverse Merger with Yumanity nbmb Therapeutics Kineta Inc KANT Stock Price News Quote History Kineta Announces Restructuring and Exploration of Strategic Oct 8 2024 Kineta Inc a clinicalstage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance announced today that it has completed Kineta Inc Transitioning from Nasdaq to OTC Markets TuHURA Biosciences Inc Enters into Definitive Merger Kineta Completes Reverse Merger with Yumanity Therapeutics SEATTLE Oct 04 2024 Kineta Inc OTC Pink KANT a clinicalstage biotechnology company focused on the development of Read More Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123 Kinetas VISTA blocking antibody Currently in Phase 1 Kineta Announces Clinical Collaboration with Merck to Kineta Announces Restructuring and Exploration of Strategic Kineta Unveils New VISTA Biomarker Data and KVA12123 Phase Kineta Inc is a clinicalstage biotechnology company with a focus on developing immunotherapies that transform patients lives It focuses on developing potentially differentiated Jan 3 2025 Kineta Inc is a clinicalstage biotechnology company with a focus on developing immunotherapies that transform patients lives It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy Kineta Inc Nextgeneration immunotherapies for cancer patients Feb 29 2024 Kineta a clinicalstage biotech company developing immunotherapies for cancer announces a corporate restructuring and a review of strategic alternatives The company is reducing expenses terminating its VISTA101 trial and seeking potential transactions to maximize shareholder value TuHURA Biosciences Inc Enters into Definitive Merger Press Releases Kineta Inc Apr 17 2023 Kineta Inc Jacques Bouchy EVP Investor Relations Business Development 1 2063780400 jbouchykinetaus Investor Relations John Mullaly LifeSci Advisors LLC jmullalylifesciadvisorscom Kineta Inc is a clinicalstage biotechnology company with a mission to develop nextgeneration immunotherapies that transform patients lives Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the major challenges with current cancer therapy Kineta Inc KANT Stock Price Overview Stock Analysis Sep 19 2024 Kineta stock now trades under the ticker symbol KANT on the OTC Pink Open Market platform operated by OTC Markets Group Inc Kineta remains committed to maintaining the highest standards of Dec 19 2022 Shares of Kineta to commence trading on Nasdaq under new ticker symbol KA on December 19 2022SEATTLE Dec 19 2022 GLOBE NEWSWIRE Kineta Inc Kineta or the Company a glowin88vip Oct 17 2022 Kinetas VISTA blocking immunotherapy KVA12123 formerly referred to as KVA121 to be evaluated in patients with advanced solid tumors Clinical trial anticipated to begin in late 2022 Kineta fills a void in the biopharmaceutical industry by efficiently advancing firstinclass novel immunotherapies from discovery to proof of concept Press Alt1 for screenreader mode Alt0 to cancel Feb 29 2024 In 2022 Kineta swooped in to rescue Yumanitys immunotherapy from the scrapheap Now Kineta needs some rescuing itself After a strategic review the small oncology biotech is conducting a Kineta Announces Completion of Enrollment in the Nasdaq Kineta develops novel immunotherapies that target innate immunity and overcome cancer immune resistance Learn about its leadership board scientific advisory board and pipeline of potential drugs Dec 19 2022 Kineta is a clinicalstage biotechnology company that completed a reverse merger with Yumanity Therapeutics in December 2022 It is focused on developing nextgeneration immunotherapies to address cancer immune resistance such as KVA12123 a VISTA blocking antibody Overview Kineta Inc Cancer Immunotherapy TuHURA Biosciences to Acquire Kineta About Us Kineta Inc Dec 12 2024 TuHURA Biosciences Inc NASDAQHURA TuHURA a Phase 3 registrationstage immuneoncology company developing novel technologies to overcome resistance to cancer immunotherapy and Kineta Kineta faces shutdown as private placement fails to show up TuHURA Biosciences Inc Enters into Definitive Merger Dec 12 2024 TuHURA Biosciences Inc Enters into Definitive Merger Agreement to Acquire Kineta Inc Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor KVA12123 to TuHURAs late stage pipeline Targeting Phase 2ab trial with KVA12123 in mutated NPM1 AML in 2025 Cross product and technology synergies build on TuHURAs therapeutic focus on overcoming primary and acquired resistance to Kineta is a clinicalstage biotechnology company with a mission to develop nextgeneration immunotherapies that transform patients lives Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance including Dec 12 2024 Neither TuHURA nor Kineta gives any assurance that either TuHURA or Kineta will achieve its expectations InvestorMedia Contacts TuHURA Biosciences Inc Jenene Thomas JTC Team LLC 9088240775 tuhurajtcircom Kineta Inc Investor Relations infokinetaus SOURCE TuHURA Biosciences Inc View the original press release on accesswirecom Feb 29 2024 Kineta Inc SEATTLE Feb 29 2024 GLOBE NEWSWIRE Kineta Inc Nasdaq KA a clinicalstage biotechnology company focused on the development of novel nagoro immunotherapies in oncology that
sangkal
planning icon
